MAP3K1 and neoplasm: Chemokines have been proposed to be potential breast cancer therapeutic targets, and our work provides evidence to support the contention that pharmacologic inhibition of MEKK1 may be one approach to reduce expression of chemokines and thereby alter the tumor microenvironment that promotes metastasis.